[3].Effects of dapagliflozin in heart failure according to duration of type 2 diabetes – a patient-level meta-analysis of DAPA-HF and DELIVER. ESC 2024. [4].McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl ...
Background: Recently, Food and Drug Administration (FDA) has approved sodium/glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However,regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, veryless information is available. Thus...
具体而言,这些抑制剂包括卡格列净、达格列净和恩格列净,它们最初分别于 2013 年 3 月【US Food and Drug Administration. Highlights of Prescribing Information — Invokana】、2014 年 1 月【US Food and Drug Administration. Highlights...
Patients with inadequate echocardiographic data at baseline to assess EVCD and incomplete information on medical therapy at discharge were excluded. Further exclusion criteria were: glomerular filtration rate < 20 ml/min/1.73 m2, active cancer, follow-up data unavailable or shorter than 6 months,...
[5]Empagliflozin in patients hospitalized for acute heart failure: the EMPULSE trial. Presented at: AHA 2021. November 14, 2021.
标题:SGLT2 Inhibitors and Stroke Risk in Patients with Type 2 Diabetes—A Systematic Review and Meta-analysis 作者:MAN GUO, YONG XU, CHENLIN GAO, Luzhou, China 时间:6月24日 周日 9:15 AM 摘要 目的:钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是治疗糖尿病的新药,同时也具有心血管获益。然而,关于SGLT...
参考文献:Zixu Zhao, Chao Jiang. et al. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis. J Am Heart Assoc. 2023 Dec 19;12(24):e031269. ...
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unk...
Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies ...
(IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in ...